🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#News: We submitted our IND for our long-acting GLP-1/GIP receptor co-agonist prodrug for #obesity. Designed for once-monthly dosing & improved GI tolerability, we hope it will provide better adherence and weight loss. Read more in the PR: investors.mbxbio.com/news-releases/…

Perfuse Therapeutics has announced positive results from its Phase 2 clinical trials for PER-001, a novel treatment for glaucoma and diabetic retinopathy. The trials showed significant improvements in vision and retinal health and a favorable safety profile. Congrats to our

Today we reported positive results on our sevasemten program for Becker and Duchenne muscular dystrophies. See our press release to learn more: investors.edgewisetx.com/news/news-deta… #Becker #Duchenne

Starting Sept 15, Cigna Healthcare will cover RhinAer (CPT 31242) for chronic rhinitis - no longer considered experimental. A major step forward in patient access to a proven treatment. AmAcadOtolaryngology #PatientAccess #ENT #ChronicRhinitis #HealthcareInnovation #AerinMedical

Our portfolio company ArriVent BioPharma announced that its interim data shows firmonertinib monotherapy achieving a 16-month median progression-free survival in first-line NSCLC patients with EGFR PACC mutations. Congrats to ArriVent on hitting this milestone for this

What a great way to start the week! AbbVie announced a definitive agreement to acquire our portfolio company, Capstan Therapeutics for $2.1 billion in cash. Capstan’s lead drug, CPTX2309, is a potentially first-in-class anti-CD 19 in vivo CAR-T therapy for the treatment of various

Arrivent, our portfolio company, has announced the pricing of its $75 million public offering of common stock, aiming to strengthen its financial position and support future growth initiatives. ir.arrivent.com/news-releases/…

Today, we announced first patient dosed in our global Phase 2 trial, VENTURE, in moderate-to-severe #COPD, marking our third pipeline indication in severe #respiratorydiseases. In #asthma, we now expect top-line data in Q1 of 2026. Learn more: bit.ly/44Bxg6S

Iambic and Revolution Medicines announced today a unique $25m tech-enablement deal giving RevMed access to NeuralPLexer, our leading AI model for predicting protein-ligand structures, to accelerate the discovery of novel oncology targets. iambic.ai/post/revolutio…

OrbiMed is thrilled to invest in Renasant Bio, a pioneering biopharmaceutical company focused on disease-modifying oral small-molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. The company has raised

We’ve released new findings from our open-label extension studies at #ENDO2025. Read more in our latest press release: bit.ly/40jlwVA

It's go time for our portfolio company, InspireMD! After its recent FDA approval, the company launched its CGuard Prime carotid stent system in the U.S. This innovative device aims to prevent strokes by minimizing embolism risk, marking a significant milestone in the company's

Our portfolio company, GentiBio, announced the FDA's acceptance of its IND application for GNTI-122, a novel Treg cell therapy aimed at preserving insulin production and preventing the progression of Type 1 Diabetes. Congrats on reaching this important milestone!

We are excited to announce an exclusive worldwide licensing agreement with Debiopharm, building on our successful collaboration to develop lunresertib and Debio 0123. Read our press release for more details: bit.ly/3GPSQwF #PKMYT1 #WEE1 #precisiononcology

Our portfolio company Brenig Therapeutics has a lot of new assets: from a new CEO and CMO to the acquisition of a pre-clinical candidate, BT-409, a potential best-in-class NLRP3 inhibitor to be studied in Parkinson’s disease. BT-409 may also have broad neuro-inflammatory applications for

This content is intended for U.S. audiences only. #NEWS: Our licensing partner ALK has received approval in the United Kingdom for our treatment for allergic reactions (anaphylaxis). Read more: bit.ly/4f5KMEY #AllergyCare #Investors $SPRY

Congrats to our portfolio company, Keros Therapeutics! The first patient has been dosed in its Phase 3 RENEW trial for elritercept, targeting transfusion-dependent anemia in myelodysplastic syndromes. This milestone triggers a $10 million payment from Takeda under their global

Congratulations to our colleague Mona Ashiya on being named a General Partner of OrbiMed! Since joining OrbiMed in 2010, Mona has established herself as a leading, consistently successful investor in the life sciences venture capital ecosystem. Mona has led OrbiMed’s investments

Our portfolio company Corteria Pharma announced advancement of its CRF2 agonists, COR-1167 and COR-1389, targeting heart failure and obesity. COR-1167 enters Phase 2 trials for worsening heart failure, while COR-1389 progresses in trials for obesity and related heart conditions.